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SObjective: Our objective was to investigate the capacity of a pumpless extracorporeal lung membrane (iLA)
(Novalung; Novalung GmbH, Hechingen, Germany) to provide adequate respiratory support and the impact
on morbidity/mortality during complex airway reconstruction.
Methods:Only patients unable to be ventilated via conventional intubation were eligible for the study. A larynx
mask or orotracheal tubes were placed above the airway defect and the iLA was attached via femoral vessels
(arteriovenous), providing extracorporeal gas exchange, apneic hyperoxygenation, and total tubeless airway re-
construction. Haptoglobulin, plasmin–antiplasmin complex, P-selectin activation, and interleukin 6 were mea-
sured before, during, and after iLA use and 72 hours postoperatively.
Results: Fifteen consecutive patients (age, 42  17 years) underwent elective (n ¼ 7) or emergency (n ¼ 8)
reconstruction of the airway owing to a variety of disorders or defects. The iLAwas left in place for 185  61
minutes, diverted 1.70  0.48 L/min of the cardiac output, and provided an arteriovenous carbon dioxide re-
moval and oxygen transfer of 173 94 and 144 83 mL/min, respectively. The arterial oxygen tension/inspired
oxygen fraction (314  31 mm Hg), and arterial carbon dioxide tension (40  6 mm Hg) remained stable
throughout the entire operations. The following procedures were performed: redo slide tracheoplasties
(n ¼ 3), redo tracheoesophageal fistula repair (n ¼ 1), sleeve lobectomies (n ¼ 2), main carina reconstructions
(n ¼ 7), and anastomotic stenting and myocutaneous coverages (n ¼ 2). Three patients required prolonged
(9  2 days) postoperative iLA support. Two (13%) patients died during the hospital stay. The use of iLA
was associated with significant (P < .05) but clinically nonrelevant and yet nonpathologic increases of
haptoglobulin (hemolysis), plasmin–antiplasmin complex (coagulation activation), and P-selectin activation
(platelet activation). Data normalized within 48 hours postoperatively.
Conclusions:Data suggest that iLA provides complete intraoperative respiratory support in patients who cannot
receive conventional intubation/ventilation without relevant effects on cellular trauma, coagulatory response,
and inflammatory response. (J Thorac Cardiovasc Surg 2012;144:425-30)Surgical resection remains the only potential curative op-
tion for a variety of thoracic malignant diseases. Some ad-
vanced thoracic afflictions, particularly in cases of airway
involvement, cannot be safely resected using conventional
ventilation techniques.1,2 Cardiopulmonary bypass (CPB)
has been described as an alternative to achieve reasonable
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The Journal of Thoracic and Caof CPB is associated with several disadvantages, such as
increased bleeding, extensive blood administration,
immunosuppressive effect, or tumor cell dissemination,
all resulting in increased morbidity and mortality.3,5,6
A relatively new extracorporeal pumpless lung mem-
brane support, the interventional lung assist (iLA)
(Novalung; Novalung GmbH, Hechingen, Germany), has
been widely described and evaluated in experimental and
clinical settings as a safe and efficient device, allowing
near-total carbon dioxide removal and moderate oxygena-
tion with minimal cellular trauma, coagulation alterations,
and immunologic response.7-11
This study was conducted to evaluate the feasibility and
efficacy of using the pumpless iLA intraoperatively in pa-
tients with thoracic diseases affecting the airways. These
patients could not be managed with a standard intubation/
ventilation protocol to perform curative resection and re-
construction owing to clinical conditions or anatomic
difficulties.rdiovascular Surgery c Volume 144, Number 2 425
Abbreviations and Acronyms
ARDS ¼ acute respiratory distress syndrome
AVCO2R ¼ arteriovenous extracorporeal carbon
dioxide removal
CPB ¼ cardiopulmonary bypass
ECMO ¼ extracorporeal membrane oxygenator
FIO2 ¼ fraction of inspiratory oxygen
iLA ¼ interventional lung assist
PaCO2 ¼ arterial carbon dioxide tension
PaO2 ¼ arterial oxygen tension
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SPATIENTS AND METHODS
From January 1, 2005, to May 1, 2008, fifteen patients took part in our
prospective study. All patients required elective or emergency complex air-
way reconstructions and could not be intubated in standard or selective pro-
cedures and thus related insufficient mechanical ventilation. Several
parameters were evaluated to study the efficacy and feasibility of using
the iLA. Adequacy of ventilation was controlled via blood gases, and me-
chanical and systemic effects of the extracorporeal device were measured
by red blood cell damage, fibrinolysis, coagulation activation, and cytokine
expression. The study was approved by the local institutional review board
and the Ethics Committee of the University of Barcelona. All patients gave
their written informed consent before surgery. In case of emergency,
informed consent was obtained from patients’ surrogates.
Eligibility Criteria
Patientswho required elective or emergencycomplexairway reconstruc-
tions were eligible for the study if standard or selective intubation and me-
chanical ventilation were technically or functionally impossible: These
include patients with ventilator-induced lung injury or acute respiratory
distress syndrome (ARDS) and severe clinical and respiratory conditions
precluding 1-lung ventilation. Also included were patients with extensive
airway defects requiring prolonged complex airway manipulation and
reconstruction time for whom standard intermittent ventilation alone was
not believed to be effective. Other eligibility criteriawere (1) hemodynamic
stability (mean arterial blood pressure>60mmHgwithminimal vasoactive
medication), (2) absence of peripheral arterial occlusive diseases to avoid
impaired limb perfusion after cannulation, (3) no signs of heparin-
induced thrombocytopenia, or (4) active septic shock. The criteria for an
ARDS followed the guidelines of the American–European Consensus
Conference for ARDS.1,2
Anesthetic and Intraoperative Management
All patients were assessed via a preoperative study protocol including
the medical history with physical examination, chest radiograph, hemo-
gram and biochemical profile, electrocardiogram, and, if necessary, addi-
tional examinations for cardiologic high-risk patients, such as computed
tomographic chest and cervical scan. Pulmonary function tests were per-
formed if possible.
All patients undergoing elective procedures received a thoracic epidural
catheter directly before surgical intervention to provide postoperative anal-
gesia except in the presence of contraindications or the patient’s refusal.
Anesthesia was induced using propofol (Diprivan; AstraZeneca UK
Limited, London, United Kingdom), remifentanil (Remifentanil Kern
Pharma EFG; Terrassa, Barcelona, Spain), and cisatracurium (Nimvex;
GSK, Madrid, Spain), and ceftriaxone 2 g (Rocefalin; Roche Pharma,
Madrid, Spain) was administrated as prophylactic antibiotic therapy. The
airway management was performed using an orotracheal tube placed426 The Journal of Thoracic and Cardiovascular Surgbronchoscopically above the airway defect (n ¼ 11) or larynx mask
(n ¼ 4), combined with simultaneous insertion of the iLA device. Before
the operation was performed, all patients were preoxygenated with an in-
spired oxygen fraction (FIO2) of 1.0. If possible, both lungs were ventilated
to maximize denitrogenation of the functional residual capacity and
achieve a maximal oxygen tension. Moreover, this provides an adequate
oxygenation during the apneic time period by an increase of intrapulmo-
nary oxygen storage in the residual functional capacity.
Then, the airways were opened and prepared for reconstruction while
care was taken to preserve and protect adjacent tissues and organs. During
the reconstruction of the airways, a nasogastric tube or pediatric catheter
was inserted into the distal airway to provide apneic hyperoxygenation
via an oxygen flow of 12 to 15 L/min. Pulse oximetry was continuously
monitored and arterial blood gases were intermittently monitored to man-
tain peripheral oxygen arterial saturation and partial arterial carbon dioxide
at levels greater than 90% and 35 to 45 mm Hg, respectively.
Several blood samples were taken during the operation to study different
blood markers, control arterial blood gases, and hemogram, ionogram, and
renal function.Moreover, wemonitored hemodynamic parameters, vasoac-
tive drug administration, fluids or blood products, urine output, arterial
oxygen tension (PaO2) and arterial carbon dioxide tension (PaCO2), period
of iLA support, and surgical time point. We evaluated the capacity of the
iLA to provide additional oxygen by calculating the oxygen content of
blood entering and exiting the device and multiplying the difference by
the flow rate through the device, according to the following formula:
Oxygen transfer ðmL=minÞ ¼ð½Oxygen content as volume percent
310 dL=LÞ3iLA flow rate ðL=minÞ:
Arteriovenous extracorporeal carbon dioxide removal (AVCO2R)
provided by the iLAwas calculated as follows:
AVCO2R ðmL=minÞ ¼ Carbon dioxide content in the inflow arterial
cannulaCarbon dioxide content in the venous
outflow cannula ðmL carbon dioxide=
100 mL bloodÞ3Blood flow iLA ðL=minÞ310:
When the surgical procedure was completed we initiated weaning and
iLA device removal in the majority of the patients, except 3 who required
prolonged iLA support during intensive care unit stay.
Management of the iLA
Before the operation, an ultrasound study of femoral vessels was made
to measure internal diameter of common femoral arteries and rule out vas-
cular disease and venous abnormalities. The femoral artery (13F or 15F)
and vein (15F or 17F) were then cannulated in the operating room by
specially designed cannulas. Cannula size was dependent on the internal
artery diameter (at least 20% smaller than the internal artery diameter to
avoid limb ischemia). A venous cannula (one size bigger than the arterial
cannula) was placed in the contralateral leg.
The cannulas were inserted using the Seldinger technique to avoid ves-
sel trauma but assure that the guide wire, dilator, and cannulas could move
freely. Then, cannulas were flushed out with a bolus of 50 mL of
heparinized saline solution (heparin doses 10-20 IU/kg body weight) and
clamped proximal. The iLA device was entirely deaired and filled with nor-
mal saline solution (250 mL) before cannulation. Before unclamping, all
connections were secured and unclamping was performed progressively
for 1 to 2 minutes to minimize impact on hemodynamics. The oxygen
line was connected to the inflow port of the iLA, and an initial flow rate
(sweep gas) of 1 L/min was set up to provide a pressure gradient at the
membrane level to enhance gaseous diffusion. At the time of tracheal
reconstruction, we performed an apneic hyperoxygenation with removal
of carbon dioxide through the iLA system. During the surgical procedure
the gas exchange (oxygen and carbon dioxide) was monitored via bloodery c August 2012
TABLE 1. Characteristics of the patients
Characteristics Numbers
Gender (male vs female) 9/6
Age (y) 42  17
Type of surgery (elective/emergency) 7/8
Indications
Failed supracarinal tracheal resection 4
Chronic tracheoesophageal benign fistula 1
Postcarinal pneumonectomy anastomotic dehiscence 2
Lung mass in a woman who was 6 m pregnant 1
Complete loss of the tracheobronchial membraneous wall 4
Main carinal perforation 3
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Ssamples (arterial side) and amount of carbon dioxide removal regulated
with the sweep gas flow (between 1 and 15 L/min). The blood flow through
the iLA device was monitored by a flowmeter (Novalung; Emtec) placed at
the outflow venous line. Cardiac output and arterial pressure were
measured and fluids or vasoactive drugs (dopamine, norepinephrine)
administrated if necessary. The arterial pressure was maintained at
60 mm Hg or higher with a blood flow rate through the iLA of around
1 L/min or higher. To assure sufficient peripheral circulation, we placed
a pulse oximeter on the leg with the arterial cannula.
Sedation was determined at the operation’s end point and weaning was
induced according to standard ventilation protocols. Simultaneously,
sweep gas flow was reduced progressively under the control of arterial
blood gases. The iLAwas typically removed when the arterial oxygen sat-
uration was greater than 95% at an FIO2 of 0.5 or more, and a physiologic
carbon dioxide measurement and decannulation were performed according
to transcutaneous technique principles.
Analyses of Plasma Markers
Laboratory values of blood samples were taken from all patients and
analyzed at the following time points: (1) before iLA implantation (base-
line), (2) 10 minutes after initiating extrapulmonary ventilation, (3) 2 hours
after starting the procedure (intraoperative), (4) after iLA removal, and (5)
72 hours after surgery. The following plasma markers were monitored
owing to their respective impact during the extracorporeal period: tissue/
cell damage via the plasma levels of lactate dehydrogenase (reference
values, 100-190 IU/L) and haptoglobin (reference values, 0.3-2.0 g/L) as
a sign for hemolytic anemia (especially intravascular hemolysis); the
activation of the fibrinolytic system via the determination of the plasma
plasmin–antiplasmin complex (reference values, 120-700 mg/L);
the activation of platelets and thus coagulation via the plasma P-selectin
(Human P-Selectine/CD62P DuoSet ELISA Development Kit; R&D
Systems, Minneapolis, Minn); and inflammatory response via the
plasma interleukin 6 (ELISA Kit; R&D Systems) (reference values,
0.428-12.95 pg/mL).
Statistical Analysis
Data collected are presented as mean standard deviation and were an-
alyzed using SPSS Statistical Package forWindows (SPSS 12.0; SPSS, Inc,
Chicago, Ill). Data recorded during the procedure were compared with
baseline data (pre-iLA). Continuous data were assessed for normality
and tested using the 2-tailed paired sample Student test. Mortality was de-
fined as death within 30 days of surgery.TABLE 2. Respiratory variables during intraoperative extracorporeal
lung membrane support
Variables iLA support
Time (min) 185  61
Tidal volume (mL/kg) 2.4  0.5
Respiratory frequency (beats/min) 6  1
FIO2 0.5  0.2
PaO2/FIO2 (mm Hg) 314  31
PaCO2 (mm Hg) 40  6
AVCO2R (mL/min) 173  94
Oxygen transfer (mL/min) 144  83
PEEP (cm H2O)* 12.3  2.6*
iLA, Interventional lung assist; Fio2, fraction of inspiratory oxygen; Pao2, arterial ox-
ygen tension; Paco2, arterial carbon dioxide tension; AVCO2R, arteriovenous carbon
dioxide removal; PEEP, positive end-expired pressure. *During the period of no open
airway (near static ventilation). There was no PEEP during open airway and apneic
oxygenation.RESULTS
The study included 15 consecutive patients (Table 1)
(9 male and 6 female) with a median age of 42  17 years
who underwent complex reconstruction of the airway using
extracorporeal pumpless membrane support. Seven patients
were managed under elective and 8 under emergency con-
ditions. Three patients were already intubated at the time
of surgery owing to respiratory disorders and 12 had elec-
tive procedures. Indications for surgery differed as follows:
(1) unsuccessful supracarinal tracheal resection (n¼ 4), (2)
chronic tracheoesophageal benign fistula (n ¼ 1), (3) post-
carinal pneumonectomy anastomotic dehiscence (n ¼ 2),
(4) lung mass in a woman who was 6 months pregnant
(n¼ 1), (5) complete loss of tracheobronchial membranous
wall (n ¼ 4), and (6) main carinal perforation (n ¼ 3).
The mean ratio of partial pressure of arterial oxygen
(PaO2) to the fraction of inspired oxygen (FIO2) (PaO2/FIO2The Journal of Thoracic and Caratio) preoperatively was 196  71 mm Hg and all except
the 3 preoperatively intubated patients had an epidural
catheter.
The iLA (Table 2) was inserted in the operating room into
all patients before the operation according to the technique
previously described without any complications. The de-
vice was left in place for 185  61 minutes with a median
flow of 1.70  0.48 L/min and allowed an oxygen transfer
and carbon dioxide removal (AVCO2R) of 144  83 mL/
min and 173  94 mL/min, respectively; consequently,
the respiratory settings of the mechanical ventilation during
iLA support could be significantly decreased to nearly static
ventilation (tidal volume, 2.4 0.5 mL/kg; respiratory rate,
6 1 breaths/min; positive end-expiratory pressure, 12.3
2.6 cm H2O), maintaining a PaO2/FIO2 and PaCO2 of 314 
31 mm Hg and 40 6 mm Hg, respectively, avoiding an in-
crease of respiratory damage owing to the mechanical ven-
tilation, and allowing an extended apneic oxygenation
period for the airway reconstruction when the mechanical
ventilation was stopped. The mean time of apneic oxygen-
ation needed mainly during airway reconstruction after dis-
section was 36  8 minutes.
The operations performed in this series included the
following: redo slide tracheoplasties (n ¼ 3), redordiovascular Surgery c Volume 144, Number 2 427
FIGURE 1. Dynamic of lactate dehydrogenase (LDH) and haptoglobin
level before interventional lung assist (iLA) placement (pre-iLA), during
iLA function (on-iLA: 10 minutes and 2 hours after initiating iLA, and
iLA removal), and after iLA removal (post-iLA).
FIGURE 3. Dynamic inflammatory response (interleukin 6) level before
interventional lung assist (iLA) placement (pre-iLA), during iLA function
(on-iLA: 10 minutes and 2 hours after initiating iLA, and iLA removal),
and after iLA removal (post-iLA).
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Stracheoesophageal fistula repair (n¼ 1), sleeve lobectomies
(n ¼ 2), main carina reconstructions (n ¼ 7), and anasto-
motic stenting and myocutaneous coverages (n ¼ 2). The
iLA was removed and decannulation performed according
to transcutaneous technique principles during the first
postoperative hour in all but 3 patients who had
ventilator-induced lung injury/ARDS and therefore re-
quired prolonged iLA support (9 2 days) during the inten-
sive care unit stay. Two (13%) patients died during the
hospital stay, both of ARDS refractory to protective ventila-
tion and iLA support. The mechanical ventilation duration
was 5  4 days, length of intensive care unit stay 8  3
days, and total hospital stay 21  6 days.
During the iLA period, several plasma markers increased
significantly (P<.05): lactate dehydrogenase (Figure 1), as
a sign for hemolysis, as well as plasmin-antiplasminFIGURE 2. Dynamic of coagulation activation (plasmin–antiplasmin
complex) and platelet activation (P-selectin) level before interventional
lung assist (iLA) placement (pre-iLA), during iLA function (on-iLA: 10
minutes and 2 hours after initiating iLA, and iLA removal), and after
iLA removal (post-iLA).
428 The Journal of Thoracic and Cardiovascular Surgcomplex and P-selectin activation, as signs for coagulation
and platelets activation, respectively (Figure 2). Moreover,
inflammatory activation was detected via interleukin 6 up-
regulation (Figure 3). Even though these changes were
statistically significant, none of the parameters reached
pathologic levels within or after the iLA period. Besides,
alterations showed no clinical relevance and normalized
within 48 hours after iLA removal.
Morbidity related to the iLA included a femoral arterial
thrombosis (1 patient) and dissection of the cannulated fem-
oral arterial (1 patient) caused by the iLA catheter insertion.
Both complications required surgical intervention after iLA
removal.DISCUSSION
The management of patients with extended airway de-
fects/disorders continues to be clinically challenging.
In cases that include extensive tracheal lesions for which
conventional resection with end-to-end anastomosis cannot
be considered, different techniques and solutions have been
described.12-14 Yet, postoperative mortality and morbidity
are rather common and related to intraoperative airway
manipulation and the use of high-pressure ventilation.15
Increased ventilation settings result in epithelial irritation,
inflammation, suture stress, and direct trauma of the newly
reconstructed airway. Moreover, complex interventions on
the airways are associated with difficulties to maintain ade-
quate ventilation. The interruption of mechanical ventila-
tion during the reconstruction, in particular, results in
deficient oxygenation, insufficient ventilation (carbon
dioxide removal), and the development of atelectasis.16,17
Therefore, an alternative to provide sufficient ventilation
during complex airway operations is absolutely required.
Different alternatives have been implemented. The oldestery c August 2012
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Soption in this context is the use of CPB. The use of CPB has
been described in several articles with good surgical results.
Unfortunately high complications rates (eg, coagulation and
platelet alteration, immunosuppression, extensive bleeding,
and dissemination of tumoral cells) lead to increased
morbidity and mortality levels during and after the use of
CPB.3-5 During the past decades, the extracorporeal
membrane oxygenator (ECMO) has been described as an
alternative to CPB in resections of extensive malignant
disease not affecting the heart, aortic arch, or pulmonary
trunk. ECMO is a method that uses a venoarterial or
a venovenous system and may become the standard
device for extracorporeal lung assist therapy owing to the
better results regarding mortality and morbidity compared
with CPB. However, associated complications such as
thromobocytopenia, thromoboembolic events, bleeding
complications, and capillary leak syndromes remain
prevalent, and lung injury and multiorganic failure are
frequently encountered.18,19 Furthermore, the complex
equipment requires a well-trained medical staff in dedicated
units to guarantee adequate management of ECMO therapy.
Using the iLA in combination with an apneic ventilation
protocol, our data provide evidence of optimal gas ex-
change during complex airway reconstruction (Table 2).
Apneic hyperoxygenation (including preoxygenation and
hyperventilation with 1.0 oxygen) allows for total apnea
but adequate oxygenation for 10 to 20 minutes during air-
way operations.20,21 This apneic period is dramatically
reduced in patients with pulmonary disease. Another
crucial factor is the dramatic increase of PaCO2 during the
apneic period owing to a lack of ventilation. Using the
extracorporeal pumpless iLA could increase the apneic
time (mean time in our study, 36  8 minutes) to perform
airway reconstruction for this distinct patient cohort
without increasing the intraoperative risks, and this was
recently confirmed by Wiebe and associates.22
ECMO-associated problems such as blood cell trauma
and systemic inflammatory response are caused by the use
of blood pumps and blood–material interactions.23,24
These complications can be minimized by using
a pumpless device like the iLA. Besides, compared with
ECMO, the small extracorporeal surface area of the
iLA reduces the blood–material platelet activation
significantly. The small surface avoids the need for high
blood volumes or specific heater installations to stabilize
blood temperature. In addition, less cell trauma and
inflammatory response are detected. Experimental and
clinical data support the concept that the iLA device
causes minimal cell trauma and inflammatory
response.7,8,18 Parameters associated with tissue/cell
damage, activation of the fibrinolytic system, activation of
the coagulation, and inflammatory response (Figures 1 to
3) showed a significant (P> .05) increase in our study
during the iLA period. The findings may promote theThe Journal of Thoracic and Caassumption that the use of the iLA may be contraindicated
for this specific patient cohort. However, all described
parameters remained within the physiologic range, did not
reach pathologic levels, and revert rapidly after iLA
removal back to baseline values. Notably, the total iLA
period coincided with the span of surgery time. The
described increase of parameters correlates directly with
the complexity of the surgical procedure.
In conclusion, our results suggest that the pumpless
extracorporeal lung membrane (iLA) is a very effective
and promising strategy in patients who cannot be managed
with a standard intubation and mechanical ventilation. The
device provides a complete intraoperative respiratory sup-
port when combined with an apneic ventilation protocol,
and this will prolong the period of surgical intervention of
the airways. The avoidance of significant cellular trauma
and coagulatory and inflammatory response represents the
basic principle of the concept and allows for safe airway
reconstruction without increased risks of perioperative
and postoperative morbidity and mortality. More patients
must be managed with this extracorporeal lung membrane
device before definite predications for potential guidelines
of using this method can be made.References
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